Form 4: Enliven Therapeutics Executive Acquires 171,000 Stock Options

Joseph P. Lyssikatos, Chief Scientific Officer of Enliven Therapeutics, acquired 171,000 stock options on February 6, 2025.

Summary

• Joseph P. Lyssikatos, the Chief Scientific Officer of Enliven Therapeutics, Inc. (ELVN), filed a Form 4 on February 10, 2025, reporting a transaction.
• On February 6, 2025, Lyssikatos acquired 171,000 stock options with an exercise price of $22.47.
• These options vest over time, with 1/4th vesting on February 6, 2026, and the remaining 1/48th vesting monthly thereafter, contingent upon continued service.
• Following the transaction, Lyssikatos directly owns 171,000 derivative securities (stock options).

Sentiment

Score: 6

Explanation: The document itself is neutral, simply reporting a transaction. The sentiment is slightly positive as it reflects an executive's increased stake in the company, suggesting confidence.

Positives

• The acquisition of stock options by a key executive could be seen as a positive sign, indicating confidence in the company's future performance.

Future Outlook

The vesting schedule suggests a long-term commitment from the executive, aligning their interests with the company's success over the coming years.

Industry Context

This filing is a routine disclosure related to executive compensation and is common in publicly traded companies. It provides transparency into the holdings and transactions of company insiders.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the biotechnology industry, used to incentivize performance and align executive interests with shareholder value.
• The vesting schedule of these options is typical, with a cliff vesting period followed by monthly vesting, which is a common practice to ensure continued service.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholder sentiment, as it signals confidence from a key executive.

Key Dates